CompletedNCT03337646
Lisdexamfetamine in Children With ADHD and Autism
About this title
Read the official source — NCT03337646Medication studyAges 6–12Canada
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- OttawaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: September 26, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 48
- Sponsor
- JPM van Stralen Medicine Professional
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT03337646
- Official title
Show the full official title
A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ottawa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is JPM van Stralen Medicine Professional, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine Dimesylate.
Who was this study for?
Listed age limits: 6 years to 12 years.
